Table 4.
Observed (O) and Expected (E) Numbers of Studies with Statistically Significant (P < 0.05) Results in AlzGene Meta-Analyses with Formally Statistically Significant Associationsa
| Gene | Polymorphism | Odds Ratio | 95% Confidence Interval | No. of Studies | O |
E |
P Value |
||
| Main Analysis | Sensitivity Analysis 1 | Main Analysis | Sensitivity Analysis 1 | ||||||
| ACE | rs1800764 (ACE7) | 0.83 | 0.72, 0.95 | 5 | 0 | 1.09 | 0.44 | 0.59 | 1.00 |
| ACE | rs4291 (ACE6) | 0.86 | 0.75, 0.99 | 5 | 0 | 0.72 | 0.34 | 1.00 | 1.00 |
| ACE | rs4362 (ACE2) | 0.83 | 0.70, 0.99 | 3 | 0 | 0.63 | 0.27 | 1.00 | 1.00 |
| APOC1 | Ins/del (HpaI)b | 2.07 | 1.67, 2.57 | 13 | 8 | 10.79 | 5.32 | 0.05 | 0.16 |
| APOE promoter | rs405509 (Th1/E47cs) | 0.79 | 0.71, 0.87 | 15 | 5 | 5.88 | 2.03 | 0.79 | 0.04* |
| APOE promoter | rs440446 (+113) | 0.58 | 0.50, 0.68 | 4 | 3 | 3.68 | 1.92 | 0.28 | 0.36 |
| APOE promoter | rs449647 (−491) | 0.72 | 0.63, 0.81 | 36 | 13 | 10.79 | 4.01 | 0.47 | ≤0.001* |
| CH25H | rs13500 | 1.44 | 1.08, 1.93 | 7 | 4 | 2.46 | 0.86 | 0.25 | 0.01* |
| CHRNB2 | rs4845378 | 0.67 | 0.50, 0.90 | 4 | 1 | 0.95 | 0.35 | 1.00 | 0.30 |
| CST3 | 5′-UTR-157 | 1.23 | 1.03, 1.47 | 4 | 0 | 0.79 | 0.33 | 1.00 | 1.00 |
| CST3 | 5′-UTR-72 | 1.28 | 1.05, 1.56 | 3 | 0 | 0.81 | 0.30 | 0.57 | 1.00 |
| CST3 | rs1064039 | 1.15 | 1.02, 1.31 | 9 | 1 | 1.04 | 0.57 | 1.00 | 0.44 |
| DAPK1 | rs4877365 | 0.80 | 0.69, 0.92 | 3 | 1 | 1.27 | 0.44 | 1.00 | 0.38 |
| DAPK1 | rs4878104 | 0.87 | 0.79, 0.95 | 6 | 1 | 1.49 | 0.60 | 1.00 | 0.47 |
| DNFB31 | rs2274159 | 1.18 | 1.05, 1.34 | 3 | 1 | 0.99 | 0.37 | 1.00 | 0.33 |
| GAPDHS | rs12984928 | 0.82 | 0.71, 0.95 | 3 | 1 | 1.24 | 0.44 | 1.00 | 0.38 |
| GAPDHS | rs4806173 | 0.81 | 0.71, 0.94 | 3 | 2 | 1.34 | 0.46 | 0.59 | 0.06* |
| IL1b | rs1143634 (+3953) | 1.18 | 1.03, 1.34 | 7 | 1 | 0.98 | 0.47 | 1.00 | 0.39 |
| LOC439999 | rs498055 | 1.18 | 1.03, 1.34 | 7 | 3 | 1.83 | 0.70 | 0.39 | 0.03* |
| LPL | rs320 (HindIII) | 0.73 | 0.59, 0.90 | 3 | 1 | 1.15 | 0.40 | 1.00 | 0.35 |
| MAPT | rs1467967 (promoter) | 0.86 | 0.75, 1.00 | 4 | 0 | 0.65 | 0.31 | 1.00 | 0.56 |
| MAPT | rs242557 (promoter) | 1.34 | 1.01, 1.53 | 4 | 0 | 1.20 | 0.45 | 0.59 | 0.07* |
| MAPT | rs2471738 (intron 9) | 1.42 | 1.20, 1.70 | 4 | 2 | 1.89 | 0.64 | 1.00 | 0.12 |
| NCSTN | −119 intron 16 | 1.38 | 1.03, 1.83 | 3 | 1 | 0.72 | 0.31 | 0.56 | 0.28 |
| POMT1 | rs2018621 | 1.70 | 1.24, 2.34 | 3 | 2 | 1.34 | 0.42 | 0.59 | 0.05* |
| PON1 | rs662 (R192Q) | 0.86 | 0.77, 0.97 | 8 | 1 | 1.02 | 0.51 | 1.00 | 0.41 |
| PRNP | rs1799990 (M129V) | 0.89 | 0.81, 0.98 | 10 | 1 | 1.26 | 0.69 | 1.00 | 0.51 |
| SOAT1 | rs1044925 | 1.31 | 1.11, 1.55 | 4 | 1 | 1.26 | 0.45 | 1.00 | 0.38 |
| SORCS1 | rs600879 | 1.24 | 1.04, 1.47 | 4 | 1 | 0.85 | 0.37 | 1.00 | 0.32 |
| SORL1 | rs2070045 | 1.20 | 1.02, 1.41 | 5 | 1 | 1.55 | 0.60 | 1.00 | 0.47 |
| SORL1 | rs2282649 | 1.14 | 1.03, 1.26 | 5 | 1 | 1.00 | 0.44 | 1.00 | 0.37 |
| SORL1 | rs3824968 | 1.21 | 1.01, 1.45 | 5 | 2 | 1.83 | 0.67 | 1.00 | 0.13 |
| SORL1 | rs661057 | 0.84 | 0.73, 0.96 | 5 | 1 | 1.81 | 0.63 | 0.66 | 0.49 |
| SORL1 | rs668387 | 0.82 | 0.69, 0.98 | 5 | 2 | 2.10 | 0.74 | 1.00 | 0.16 |
| TF | rs1049296 (P570S) | 1.21 | 1.07, 1.39 | 13 | 2 | 1.92 | 0.90 | 1.00 | 0.23 |
| TFAM | rs2306604 | 0.78 | 0.62, 0.98 | 3 | 0 | 0.62 | 0.23 | 1.00 | 1.00 |
| TGFB1 | rs9282871 (Leu10Pro) | 0.87 | 0.77, 0.99 | 3 | 0 | 0.67 | 0.29 | 1.00 | 1.00 |
| TNF | −863 | 0.71 | 0.53, 0.96 | 3 | 2 | 1.01 | 0.37 | 0.26 | 0.04* |
| TNF | rs4647198 (−1031) | 1.37 | 1.05, 1.78 | 3 | 1 | 0.73 | 0.26 | 0.57 | 0.24 |
| hCG2039140c | rs1903908 | 1.23 | 1.06, 1.44 | 4 | 0 | 1.03 | 0.42 | 0.58 | 1.00 |
Abbreviations: ACE, angiotensin-converting enzyme; ABCA1, ATP-binding cassette transporter A1; APOC1, apolipoprotein C1; APOE, apolipoprotein E; CH25H, cholesterol 25-hydroxylase; CHRNB2, cholinergic receptor, nicotinic, beta 2; CST3, cystatin 3; DAPK1, death-associated protein kinase 1; DFNB31, deafness, autosomal recessive 31; GAPDHS, glyceraldehyde-3-phosphate dehydrogenase, spermatogenic; IL1b, interleukin-1b; LOC439999, similar to ribosomal protein S3a; LPL, lipoprotein lipase; MAPT, microtubule-associated protein; NCSTN, nicastrin; POMT1, protein-O-mannosyltransferase 1; PON1, paraoxonase 1; PRNP, prion protein; SOAT1, sterol O-acyltransferase 1; SORCS1, sortilin-related VPS10 domain containing receptor 1; SORL1, sortilin-related receptor, L(DLR class) A repeats-containing; TF, transferring; TFAM, transcription factor A, mitochondrial; TGFB1, transforming growth factor, beta 1; TNF, tumor necrosis factor; UTR, untranslated region.
P < 0.10 for an excess of O over E.
The main results assume that the plausible effect in each meta-analysis is given by the summary effect (odds ratio) of the meta-analysis. Also shown are results from evaluations using half of the log odds ratio (“Sensitivity Analysis 1”) as the plausible effect.
Note that for this polymorphism, there is seemingly an excess of E over O—probably a chance finding resulting from the high number of analyses conducted. The signal of this single nucleotide polymorphism is probably due to high linkage disequilibrium with the APOE ϵ2/3/4 single nucleotide polymorphism.
This gene does not yet have an official name.